Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2014

View Archived Issues

Doxofylline receives FDA orphan drug status for bronchiectasis

ONC1-13B shows high efficacy in preclinical models of prostate cancer

ProTide technology applied to anticancer agents to overcome drug resistance

BioAtla grants BioMotiv worldwide rights to IL-22 antibody

Pivotal trial of LDE-225 in advanced basal cell carcinoma meets primary endpoint

CURx Pharmaceuticals enters into license agreement with Gilead Sciences

Phase III ramucirumab lung cancer trial meets primary endpoint of overall survival

Zealand Pharma prepares novel glucagon receptor agonists

Insmed provides interim update from extension study of Arikace in cystic fibrosis

Omeros doses first patient in second phase II trial of OMS-824

Oritavancin NDA accepted by FDA for filing

Researchers at Proximagen present new PAR-2 antagonists

Preclinical results presented for RTL-1000 as a therapeutic agent for stroke

Actavis to acquire Forest Laboratories

Cellceutix submits IND for Prurisol trial, begins enrollment in phase IIb trials of brilacidin

Onconova discloses results from phase III trial of intravenous rigosertib in higher risk MDS

Nerviano Medical Sciences discloses novel JAK inhibitors

Michael J. Fox Foundation awards grant to Ezose Sciences

New H+/K+-ATPase inhibitors designed for gastrointestinal and other disorders

Bayer begins phase III COAST trial of regorafenib

Korean group prepares novel MAbs for cancer

PAK-01 enhances reperfusion and neuroprotection with no hemorrhagic transformation in vivo

Dilafor and Lee's Pharmaceutical sign license agreement for tafoxiparin in China

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...